Analysis: Complexity lies ahead for CRISPR patents after PTAB decision
The eagerly-anticipated ruling from the PTAB of “no interference-in-fact” is a win for the Broad Institute in its CRISPR patent battle with University of California Berkeley. But much wrangling lies ahead over the rights to the gene-editing technology, including a potential appeal and likely licensing disputes
The Patent Trial and Appeal Board (PTAB) ruled on February 15 that the Broad Institute of Harvard and MIT’s patents for CRISPR-Cas9 technology were valid and “cause no interference-in-fact” with the University of California Berkeley (UC Berkeley)’s patent applications for...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.